BMS patent winner

Koroneos, George
March 2009
Pharmaceutical Representative;Mar2009, Vol. 39 Issue 3, p8
The article reports that Bristol-Myers Squib (BMS) topped the IFI Patent Intelligence. It says that BMS landed as the patent winner for the second year after it garnered 88 patent approvals. Darlene Slaughter, general manager at IFI states that patents are not only an indicator of the company's success but also the key to get through the Food and Drug Administration (FDA) approval process.


Related Articles

  • New drug marks advance in treatment of hepatitis B. LoBuono, Charlotte // Drug Topics;5/2/2005, Vol. 149 Issue 9, p25 

    This article announces the approval of entecavir from Bristol-Myers Squibb Co. for the treatment of chronic hepatitis B virus infection in adults by the U.S. Food and Drug Administration. Entecavir Tablets are currently available in pharmacies in the country. entecavir is a guanosine nucleoside...

  • Pharma: Other News To Note.  // BioWorld Today;1/ 3/2013, Vol. 24 Issue 2, p7 

    The article reports on the approval of the Eliquis drug from Bristol-Myers Squibb Co. and Pfizer Inc. by U.S. Food and Drug Administration (FDA).

  • Medarex/Britol-Myers: another setback in melanoma.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p13 

    The author reflects on the delay in the submission of ipilimumab's Biologics License application of Medarex Inc. and Bristol-Myers. According to the author, the setback following the request by the U.S. Food and Drug Administration (FDA) for additional survival data could bring forth worries for...

  • Bristol-Myers Squibb: Sprycel wins full approval in US.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p11 

    The article reports on the approval of the U.S. Food and Drug Administration on Bristol-Myers Squibb Co.'s Sprycel for treatment of chronic myeloid leukemia (CML). The drug is an oral targeted therapy that inhibits several tyrosine kinases and is also indicated for Philadelphia-positive acute...

  • Melanoma drug wins US approval. Ledford, Heidi // Nature;3/31/2011, Vol. 471 Issue 7340, p561 

    The article offers information on the approval of melanoma drug by the Food and Drug Administration (FDA) in the U.S. On March 25, 2011, the FDA cleared the drug for ipilimumab by Bristol-Myers Squibb for the treatment of advanced melanoma. Moreover, the drug is said to lengthen the life of the...

  • NEW INDICATIONS.  // Drug Topics;10/6/2003, Vol. 147 Issue 19, p115 

    Features U.S. Food and Drug Administration-approved Valtrex or Features drugs that have been approved by the U.S. Food and Drug Administration for new indications in October 2003. Valtrex or valacyclovir HCl caplets from GlaxoSmithKline, for suppressive therapy in healthy adults with genital...

  • First Depression Patch Approved.  // FDA Consumer;May/Jun2006, Vol. 40 Issue 3, p4 

    The article reports on the U.S. Food and Drug Administration approval of the skin patch Emsam for treating major depression in 2006. Bristol-Myers' skin patch delivers selegiline, a monoamine oxidase inhibitor, through the skin and into the bloodstream. Emsam layers consist of a backing,...

  • FDA strips breakthrough status.  // Nature Biotechnology;Mar2015, Vol. 33 Issue 3, p226 

    The article reports that U.S. Food and Drug Administration (FDA) revoked a breakthrough designation for two drugs of the New York-based Bristol-Myers Squibb Co. (BMS), which treat hepatitis C virus (HCV).

  • FDA Approves YERVOY(tm) (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer.  // Biomedical Market Newsletter;4/30/2011, p350 

    The article announces the approval of YERVOYâ„¢ or ipilimumab from Bristol-Myers Squibb Co. in Princeton, New Jersey has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients diagnosed with unresectable with metastatic melanoma. The drug has been the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics